Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Monday, 2 October 2017

Novo Nordisk A/S - Share repurchase programme

Novo Nordisk A/S    

Published: 14:07 CEST 02-10-2017 /GlobeNewswire /Source: Novo Nordisk A/S / : NOVO B /ISIN: DK0060534915

Novo Nordisk A/S - Share repurchase programme

 

Bagsværd, Denmark, 2 October 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 16 billion to be executed during a 12-month period beginning 2 February 2017.

 

Under the programme initiated 9 August 2017, Novo Nordisk will repurchase B shares for an amount up to DKK 3.9 billion in the period from 9 August 2017 to 30 October 2017.

 

Since the announcement as of 25 September 2017, the following transactions have been made under the programme:

 

 

Number of

B shares

Average

purchase price

Transaction

value, DKK

Accumulated, last announcement

7,499,590

 

2,205,950,196

25 September 2017

210,000

308.05

64,691,388

26 September 2017

220,000

303.69

66,812,522

27 September 2017

210,000

302.86

63,600,266

28 September 2017

215,000

303.85

65,328,427

29 September 2017

215,000

301.53

64,829,174

Accumulated under the programme

8,569,590

 

2,531,211,974

 

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

 

With the transactions stated above, Novo Nordisk owns a total of 41,621,013 B shares of DKK 0.20, corresponding to 1.7% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,500,000,000 including treasury shares.

 

Novo Nordisk expects to repurchase B shares for an amount up to DKK 16 billion during a 12-month period beginning 2 February 2017. As of 29 September 2017, Novo Nordisk has repurchased a total of 40,517,561 B shares equal to a transaction value of DKK 10,831,183,966.

 

 

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

 

Further information

Media:

 

 

Anne Margrethe Hauge

+45 4442 3450

amhg@novonordisk.com

Ken Inchausti (US)

+1 609 786 8316

kiau@novonordisk.com

 

 

 

Investors:

 

 

Peter Hugreffe Ankersen

+45 3075 9085

phak@novonordisk.com

Hanna Ögren

+45 3079 8519

haoe@novonordisk.com

Anders Mikkelsen

+45 3079 4461

armk@novonordisk.com

Christina Kjær

+45 3079 3009

cnje@novonordisk.com

Kasper Veje (US)

+1 609 235 8567

kpvj@novonordisk.com

 

 

 Company announcement No 75 / 2017




CA20171002 - Safe Harbour CA_UK.ARND



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Novo Nordisk A/S, Novo Allé, Bagsvaerd DK-2880, Denmark
If you would like to unsubscribe and stop receiving these e-mails click here.